Replies to post #205063 on Biotech Values

[Titan V]

Thanks Dew. As you may already know, Roche/Genentech are also in arena with the approval of Tecentriq.
https://www.gene.com/media/press-releases/14626/2016-05-18/fda-grants-genentechs-cancer-immunothera

I am excited about the combination therapies these players (MRK, BMY and Roche/Gene) may pursue in bladder cancer. My hunch is they will approach HTBX. (BMY and HTBX already have a combo in NSCLC with phase I data due this quarter.)

This time last year, HTBX appointed Dr. Kapil Dhingra with 9 years at Roche Oncology to its Scientific and Clinical Advisory Board.
http://ir.heatbio.com/press-releases/detail/501/heat-biologics-expands-scientific-and-clinical-advisory

If you look at his LinkedIn profile, you will see Dr. Dhingra has been on the board of 3 companies which were sold to big pharma for over $1B+ and one for over $500M+. I have a hunch HTBX will be sold after the data readouts this quarter. HTBX laid off 22% of their workforce to cut expenses earlier this year. They have not hired a replacement CFO since then. If they are planning to remain independent, I would assume they would have hired someone by now.

At the very least, if the phase 2 bladder cancer data is good, I expect one of the big pharmas to sign a partnership agreement with HTBX for phase 3. All just my speculation of course.

[DewDiligence]

FDA approves Opdivo in second-line bladder cancer:

http://finance.yahoo.com/news/bristol-myers-squibb-receives-fda-211500753.html

This is an accelerated approval based on the 20% RR (including a 3% CR rate) in the single-arm CHECKMATE-275 study.